196 related articles for article (PubMed ID: 9498799)
1. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL
Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
4. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.
Emtage PC; Wan Y; Muller W; Graham FL; Gauldie J
J Interferon Cytokine Res; 1998 Nov; 18(11):927-37. PubMed ID: 9858314
[TBL] [Abstract][Full Text] [Related]
5. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
7. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
8. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
9. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
[TBL] [Abstract][Full Text] [Related]
10. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
11. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
13. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells.
Dessureault S; Graham FL; Gallinger S
Cancer Gene Ther; 1999; 6(3):195-208. PubMed ID: 10359205
[TBL] [Abstract][Full Text] [Related]
14. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.
Palmer K; Hitt M; Emtage PC; Gyorffy S; Gauldie J
Gene Ther; 2001 Feb; 8(4):282-90. PubMed ID: 11313802
[TBL] [Abstract][Full Text] [Related]
15. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
16. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J
Hum Gene Ther; 1999 Mar; 10(5):697-709. PubMed ID: 10210138
[TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
19. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
20. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
